Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JHF, 2011. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl Trop Dis 5: e1210.
Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux J-P, 2003. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2 (Suppl 1): S4.
Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M, 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 18–22.
Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M, 2009. Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events. Am J Trop Med Hyg 81: 1056–1061.
Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG, 2010. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg 83: 28–32.
White V, Lewallen S, Beare N, Molyneux M, Taylor T, 2009. Retinal pathology of pediatric cerebral malaria in Malawi. PLoS One 4: e4317.
Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD, 2008. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg 78: 546–551.
Twum-Danso NAY, 2003. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2 (Suppl 1): S3.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 208 | 193 | 14 |
Full Text Views | 275 | 13 | 1 |
PDF Downloads | 88 | 8 | 1 |
Although ivermectin treatment can induce serious adverse events (SAEs) in individuals harboring high Loa loa microfilaremia (mf), not all patients with high mf levels develop such reactions, suggesting that cofactors may be involved. A study was conducted in Cameroon to investigate the possible role of Plasmodium coinfection at the time of ivermectin treatment in the development of SAEs. Before their first ivermectin treatment, thick smears were obtained from 4,175 individuals to determine the burden of Plasmodium sp., L. loa, and Mansonella perstans. After treatment, 18 (4.3 per 1,000) patients developed a non-neurologic SAE. Logistic regression analysis, adjusting for age, sex, P. falciparum infection, and M. perstans infection intensities, confirmed that L. loa mf was the main risk factor for SAEs. We found no evidence that coinfection with P. falciparum at the time of ivermectin treatment was associated with the occurrence of Loa-related SAEs in this population.
Authors' addresses: Joël Fokom-Domgue, Patrick Nguipdop-Djomo, and Joseph Kamgno, Center for Research on Filariasis and other Tropical Diseases, Yaounde, Cameroon, E-mails: joeldomgue@yahoo.fr, patrick.nguipdop-djomo@lshtm.ac.uk, and kamgno@crfilmt.org. Raceline Gounoue, Faculty of Sciences, University of Yaounde, Yaounde, Cameroon, E-mail: gounoue@crfilmt.org. Julie Akame, Helen Keller International, Yaounde, Cameroon, E-mail: jakame@hki.org. Nana A. Y. Twum-Danso and Björn Thylefors, Mectizan Donation Program, Decatur, GA, E-mails: ntwumdanso@yahoo.com and bthylefors@gmail.com. Sébastien D. Pion and Michel Boussinesq, UMI233, Institut de Recherche pour le Développement, Montpellier, France, E-mails: sebastien.pion@ird.fr and michel.boussinesq@ird.fr.
Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JHF, 2011. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl Trop Dis 5: e1210.
Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux J-P, 2003. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2 (Suppl 1): S4.
Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M, 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 18–22.
Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M, 2009. Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events. Am J Trop Med Hyg 81: 1056–1061.
Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG, 2010. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg 83: 28–32.
White V, Lewallen S, Beare N, Molyneux M, Taylor T, 2009. Retinal pathology of pediatric cerebral malaria in Malawi. PLoS One 4: e4317.
Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD, 2008. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg 78: 546–551.
Twum-Danso NAY, 2003. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2 (Suppl 1): S3.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 208 | 193 | 14 |
Full Text Views | 275 | 13 | 1 |
PDF Downloads | 88 | 8 | 1 |